These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 32170656)

  • 1. Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation.
    Taha MS; Padmakumar S; Singh A; Amiji MM
    Drug Deliv Transl Res; 2020 Jun; 10(3):766-790. PubMed ID: 32170656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
    Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
    Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into Active Targeting of Nanoparticles in Drug Delivery: Advances in Clinical Studies and Design Considerations for Cancer Nanomedicine.
    Pearce AK; O'Reilly RK
    Bioconjug Chem; 2019 Sep; 30(9):2300-2311. PubMed ID: 31441642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Particle Size in Translational Research of Nanomedicines for Successful Drug Delivery: Discrepancies and Inadequacies.
    Chan HW; Chow S; Zhang X; Kwok PCL; Chow SF
    J Pharm Sci; 2023 Sep; 112(9):2371-2384. PubMed ID: 37453526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook.
    Mu Q; Yu J; McConnachie LA; Kraft JC; Gao Y; Gulati GK; Ho RJY
    J Drug Target; 2018; 26(5-6):435-447. PubMed ID: 29285948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in nanomedicine clinical translation.
    Metselaar JM; Lammers T
    Drug Deliv Transl Res; 2020 Jun; 10(3):721-725. PubMed ID: 32166632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
    Hock SC; Ying YM; Wah CL
    PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translational Multi-Disciplinary Approach for the Drug and Gene Delivery Systems for Cancer Treatment.
    Nayak R; Meerovich I; Dash AK
    AAPS PharmSciTech; 2019 Apr; 20(4):160. PubMed ID: 30968269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current hurdles to the translation of nanomedicines from bench to the clinic.
    Đorđević S; Gonzalez MM; Conejos-Sánchez I; Carreira B; Pozzi S; Acúrcio RC; Satchi-Fainaro R; Florindo HF; Vicent MJ
    Drug Deliv Transl Res; 2022 Mar; 12(3):500-525. PubMed ID: 34302274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise.
    Bharali DJ; Mousa SA
    Pharmacol Ther; 2010 Nov; 128(2):324-35. PubMed ID: 20705093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging concepts in dendrimer-based nanomedicine: from design principles to clinical applications.
    Kannan RM; Nance E; Kannan S; Tomalia DA
    J Intern Med; 2014 Dec; 276(6):579-617. PubMed ID: 24995512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Quality by Design Approach to Developing and Manufacturing Polymeric Nanoparticle Drug Products.
    Troiano G; Nolan J; Parsons D; Van Geen Hoven C; Zale S
    AAPS J; 2016 Nov; 18(6):1354-1365. PubMed ID: 27631558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures.
    Ragelle H; Danhier F; Préat V; Langer R; Anderson DG
    Expert Opin Drug Deliv; 2017 Jul; 14(7):851-864. PubMed ID: 27730820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality-by-Design Concepts to Improve Nanotechnology-Based Drug Development.
    Rawal M; Singh A; Amiji MM
    Pharm Res; 2019 Sep; 36(11):153. PubMed ID: 31482243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.
    Kompella UB; Amrite AC; Pacha Ravi R; Durazo SA
    Prog Retin Eye Res; 2013 Sep; 36():172-98. PubMed ID: 23603534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular Nanomedicine: Current Status, Opportunities, and Challenges.
    Sun M; Sen Gupta A
    Semin Thromb Hemost; 2020 Jul; 46(5):524-544. PubMed ID: 31200393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Abnormality-Oriented Nanomedicine Design.
    Zhou Q; Xiang J; Qiu N; Wang Y; Piao Y; Shao S; Tang J; Zhou Z; Shen Y
    Chem Rev; 2023 Sep; 123(18):10920-10989. PubMed ID: 37713432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current developments and applications of microfluidic technology toward clinical translation of nanomedicines.
    Liu D; Zhang H; Fontana F; Hirvonen JT; Santos HA
    Adv Drug Deliv Rev; 2018 Mar; 128():54-83. PubMed ID: 28801093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Data Analytics Approach for Rational Design of Nanomedicines with Programmable Drug Release.
    Mullis AS; Broderick SR; Binnebose AM; Peroutka-Bigus N; Bellaire BH; Rajan K; Narasimhan B
    Mol Pharm; 2019 May; 16(5):1917-1928. PubMed ID: 30973741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transforming nanomedicine manufacturing toward Quality by Design and microfluidics.
    Colombo S; Beck-Broichsitter M; Bøtker JP; Malmsten M; Rantanen J; Bohr A
    Adv Drug Deliv Rev; 2018 Mar; 128():115-131. PubMed ID: 29626549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.